Journal
EXPERT REVIEW OF RESPIRATORY MEDICINE
Volume 6, Issue 2, Pages 173-186Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERS.12.12
Keywords
anti-IL-17 therapy; asthma; glucocorticoids; hallmark pathological changes of asthma; IL-17; IL-17-targeting drug; neutrophilic asthma; steroid-resistant asthma
Categories
Ask authors/readers for more resources
Expert Rev. Respir. Med. 6(2), 173-186 (2012) Asthma is perceived as a heterogeneous disease with several clinical phenotypes and triggering factors. In general, cytokines from T-helper 2 cells are believed to be critical contributors of asthma. In recent years, IL-17, another T-helper lymphocyte-associated cytokine, has been put forward as another potentially important mediator of asthma. Currently, several drugs that target IL-17 signaling are being tested in clinical trials. With the aim to find whether there are any specific features of this heterogeneous disease that potentially could be relieved by the use of IL-17-targeting drugs, this review scrutinizes the evidence for an involvement of IL-17 in human asthma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available